Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia with FLT3/ITD Mutation | Phase 3 | CN | 27 Feb 2023 | |
Adult Acute Myeloblastic Leukemia | Phase 2 | CN | 01 Oct 2022 | |
Leukemia | Phase 1 | CN | 30 Jan 2022 | |
Refractory acute myeloid leukemia | Phase 1 | CN | 18 May 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | CN | 18 May 2018 |
Phase 1 | 75 | (lwkxhlsnrs) = echclhmczy vpxhuoemdb (bpumdfndut ) View more | - | 11 Dec 2023 | |||
NCT04827069 (EHA2022) Manual | Phase 1 | 53 | (bsoynctvqe) = xwpdlefpox yztmpwsthg (impqwrkmuz ) View more | Positive | 12 May 2022 | ||
(cbfhtnakpv) = gnbjvthure ftzlyarhgs (tnsnesopnf ) View more |